Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating lenalidomide as maintenance therapy after second-line treatment in B-cell chronic lymphocytic leukemia completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Chronic Lymphocytic Leukemia

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: Celgene | Conditions: B-cell Chronic Lymphocytic Leukemia | Phase 3 | Status: COMPLETED | Results posted: 2021-12-02